|
Trial characteristic
|
Number of trials (%)
|
|---|
|
(n = 36)
|
|---|
|
Study type
| |
|
CTIMP
|
24 (67 %)
|
|
Non-CTIMP
|
9 (25 %)
|
|
Pre-screening
|
3 (8 %)
|
|
Sponsor
| |
|
Royal Marsden
|
9 (25 %)
|
|
Other academic institution
|
11 (31 %)
|
|
Pharmaceutical company
|
16 (44 %)
|
|
Phase
| |
|
I
|
2 (6 %)
|
|
II
|
10 (28 %)
|
|
II/III
|
2 (6 %)
|
|
III
|
13 (36 %)
|
|
Not applicable
|
9 (25 %)
|
|
Trial setting
| |
|
Neoadjuvant
|
3 (8 %)
|
|
Adjuvant
|
3 (8 %)
|
|
Advanced
|
16 (44 %)
|
|
Any
|
5 (14 %)
|
|
Lymphomaa
|
9 (25 %)
|
|
Randomised trial
| |
|
Yes
|
20 (56 %)
|
|
No
|
16 (44 %)
|
|
Molecular screening
| |
|
Yes
|
10 (28 %)
|
|
No
|
26 (72 %)
|
|
Number of PIS (e.g. separate pharmacodynamics or imaging sub-studies)
| |
|
1
|
20 (56 %)
|
|
2
|
11 (31 %)
|
|
3
|
4 (11 %)
|
|
5
|
1 (3 %)
|
- Key: CTIMP = Clinical Trial of an Investigational Medicinal Product, pre-screening = molecular pre-screening to determine potential eligibility for a specific CTIMP study, PIS = patient information sheet
- aLymphoma trials were considered separately as the intent of lymphoma treatment is to induce remission and, therefore, the treatment paradigms differ from that of gastrointestinal malignancies
